id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5767-0029,FDA,FDA-2017-D-5767,ANDAs for Certain Highly  Purified Synthetic Peptide  Drug Products That Refer to  Listed Drugs of rDNA  Origin Guidance for Industry,Other,Guidance,2021-05-20T04:00:00Z,2021,5,2021-05-20T04:00:00Z,,2024-11-06T23:47:57Z,,1,0,0900006484b23f31
FDA-2017-D-5767-0028,FDA,FDA-2017-D-5767,"Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to 
Listed Drugs of Recombinant Deoxyribonucleic Acid; Guidance for Industry; Availability",Notice,Notice of Availability,2021-05-20T04:00:00Z,2021,5,2021-05-20T04:00:00Z,,2021-05-25T13:29:16Z,2021-10603,0,0,0900006484b235e6